Elotuzumab plus lenalidomide and dexamethasone (ELd) in relapsed/refractory multiple myeloma (RRMM): ELOQUENT-2 post-hoc analysis of progression-free survival (PFS), tumor regrowth by time from diagnosis and prior lines of therapy, and median duration of response (DOR)

被引：0

作者：

Weisel, K. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Palumbo, A. ^{[3
]}

Richardson, P. ^{[4
]}

Mateos, M. -, V ^{[5
]}

Moreau, P. ^{[6
]}

Gupta, M. ^{[7
]}

Sheng, J. ^{[7
]}

Passey, C. ^{[7
]}

Sy, O. ^{[7
]}

Katz, J. ^{[7
]}

Lonial, S. ^{[8
]}

机构：

[1] Univ Tubingen, Tubingen, Germany

[2] Univ Athens, Alexandra Hosp, Athens, Greece

[3] AOU San Giovanni Battista Torino, Osped Molinette, Turin, Italy

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Complejo Asistencial Univ Salamanca IBSAL, Salamanca, Spain

[6] Univ Hosp, Nantes, France

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V730

引用

页码：223 / 223

页数：1

共 13 条

[1] ELOTUZUMAB plus LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2 POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM DIAGNOSIS AND PRIOR LINES OF THERAPY
Dimopoulos, M. A.
Palumbo, A.
Weisel, K.
Richardson, P.
Mateos, M. V.
Moreau, P.
Gupta, M.
Sheng, J.
Passey, C.
Sy, O.
Katz, J.
Lonial, S.
HAEMATOLOGICA, 2016, 101 : 85 - 85
[2] Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Dimopoulos, Meletios A.
Lonial, Sagar
White, Darrell
Moreau, Philippe
Palumbo, Antonio
San-Miguel, Jesus
Shpilberg, Ofer
Anderson, Kenneth
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Mateos, Maria-Victoria
Belch, Andrew
Reece, Donna
Beksac, Meral
Bleickardt, Eric
Poulart, Valerie
Sheng, Jennifer
Sy, Oumar
Katz, Jessica
Singhal, Anil
Richardson, Paul
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (06) : 896 - 905
[3] Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)
Scheid, C.
Roellig, C.
Weisel, K.
Salwender, H-J
Gramatzki, M.
Edmaier-Schroeger, K.
Sy, O.
Goldschmidt, H.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 189 - 189
[4] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
Dimopoulos, Meletios A.
Lonial, Sagar
Betts, Keith A.
Chen, Clara
Zichlin, Miriam L.
Brun, Alexander
Signorovitch, James E.
Makenbaeva, Dinara
Mekan, Sabeen
Sy, Oumar
Weisel, Katja
Richardson, Paul G.
CANCER, 2018, 124 (20) : 4032 - 4043
[5] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
Dimopoulos, Meletios A.
Weisel, Katja
Lonial, Sagar
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San-Miguel, Jesus
Anderson, Kenneth C.
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna
Beksac, Meral
Ganetsky, Alex
Jou, Ying-Ming
McKiver, Mihaela Popa
Singhal, Anil K.
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
[6] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Lonial, Sagar
Dimopoulos, Meletios
Weisel, Katja
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San Miguel, Jesus
Anderson, Kenneth
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna
Beksac, Meral
Shelat, Suresh
Sy, Oumar
Singhal, Anil
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S253 - S253
[7] Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San-Miguel, Jesus
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Shelat, Suresh
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)
Garderet, Laurent
Laubach, Jacob P.
Stoppa, Anne-Marie
Hari, Parameswaran
Cavo, Michele
Ludwig, Heinz
Mateos, Maria-Victoria
Luptakova, Katarina
Lin, Jianchang
van de Velde, Helgi
Berg, Deborah
Moreau, Philippe
Richardson, Paul G.
BLOOD, 2016, 128 (22)
[10] Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf-Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordstrom, Eva
Harmenberg, Johan
Obermueller, Jakob
Richardson, Paul G.
BLOOD, 2019, 134

← 1 2 →